within Pharmacolibrary.Drugs.ATC.L;

model L01FX22
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 8.733333333333335e-06,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,   // mg â†’ kg
    adminCount     = 1,
    Vd             = 0.00711,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00617,
    k12             = 0.697,
    k21             = 0.697
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01FX22</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Loncastuximab tesirine is an antibody-drug conjugate (ADC) composed of a CD19-directed monoclonal antibody conjugated to a cytotoxic pyrrolobenzodiazepine dimer. It is approved for use in adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adults with relapsed or refractory diffuse large B-cell lymphoma. Data are based on population PK analysis of clinical trial subjects.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01FX22;
